The global demand for Genome Editing Market is presumed to reach the market size of nearly USD 35.49 Billion by 2032 from USD 8.36 Billion in 2023 with a CAGR of 17.42% under the study period 2024-2032.
Genome editing refers to a suite of advanced biotechnological techniques that enable precise modification of an organism's genetic material. By utilizing methods such as CRISPR-Cas9, researchers can target and alter specific DNA sequences, facilitating the correction of genetic mutations, enhancement of desirable traits, or investigation of gene function. This technology holds transformative potential across various fields, including medicine, agriculture, and research, allowing for tailored genetic interventions to improve health outcomes, increase crop yields, and advance scientific understanding.
MARKET DYNAMICS
Advancements in CRISPR and other editing technologies offer more precise and accessible methods for genetic manipulation, fostering market expansion. Genome editing plays a pivotal role in biomedical research, aiding in understanding disease mechanisms, drug discovery, and potential therapies, driving its demand in the biopharmaceutical sector. The increasing prevalence of genetic disorders fuels the development of therapies targeting genetic mutations, further propelling the market. In agriculture and livestock, this editing is used to enhance traits, improve yields, and develop disease-resistant varieties, contributing to its growth in agricultural biotechnology. Supportive regulatory frameworks, increased R&D investments, and the therapeutic potential of genome editing in treating various conditions fuel market expansion. Collaborations among institutions and industry players drive innovation, leading to novel applications and therapies. Despite challenges like off-target effects and ethical concerns, the genome editing market continues to expand, driven by technological advancements and its potential to revolutionize biomedical research, agriculture, and therapeutic interventions across diverse sectors.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Genome Editing. The growth and trends of Genome Editing industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Genome Editing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Genome Editing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Genome Editing market include Merck KGaA, Cibus Inc., Recombinetics, Sangamo Therapeutics, Editas Medicine, Precision BioSciences, Crispr Therapeutics, Intellia Therapeutics Inc., Caribou Biosciences Inc, Cellectis S.A., AstraZeneca, Takara Bio Inc., Horizon Discovery Ltd. (Revvity Inc.), Danaher Corporation, Transposagen Biopharmaceuticals Inc., Genscript Biotech Corp, New England Biolabs. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
3.7.1 Market Attractiveness Analysis By Technology
3.7.2 Market Attractiveness Analysis By Delivery Method
3.7.3 Market Attractiveness Analysis By Application
3.7.4 Market Attractiveness Analysis By Mode
3.7.5 Market Attractiveness Analysis By End-use
3.7.6 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL GENOME EDITING MARKET ANALYSIS BY TECHNOLOGY
5.1. Overview By Technology
5.2. Historical and Forecast Data Analysis By Technology
5.3. CRISPR-Cas9 Historic and Forecast Sales By Regions
5.4. TALENs/MegaTALs Historic and Forecast Sales By Regions
5.5. ZFN Historic and Forecast Sales By Regions
5.6. Meganuclease Historic and Forecast Sales By Regions
5.7. Others Historic and Forecast Sales By Regions
6. GLOBAL GENOME EDITING MARKET ANALYSIS BY DELIVERY METHOD
6.1. Overview By Delivery Method
6.2. Historical and Forecast Data Analysis By Delivery Method
6.3. Ex-vivo Historic and Forecast Sales By Regions
6.4. In-vivo Historic and Forecast Sales By Regions
7. GLOBAL GENOME EDITING MARKET ANALYSIS BY APPLICATION
7.1. Overview By Application
7.2. Historical and Forecast Data Analysis By Application
7.3. Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others) Historic and Forecast Sales By Regions
7.4. Clinical Applications (Diagnostics, Therapy Development) Historic and Forecast Sales By Regions
8. GLOBAL GENOME EDITING MARKET ANALYSIS BY MODE
8.1. Overview By Mode
8.2. Historical and Forecast Data Analysis By Mode
8.3. Contract Historic and Forecast Sales By Regions
8.4. In-House Historic and Forecast Sales By Regions
9. GLOBAL GENOME EDITING MARKET ANALYSIS BY END-USE
9.1. Overview By End-use
9.2. Historical and Forecast Data Analysis By End-use
9.3. Biotechnology and Pharmaceutical Companies Historic and Forecast Sales By Regions
9.4. Academic and Government Research Institutes Historic and Forecast Sales By Regions
9.5. Contract Research Organizations Historic and Forecast Sales By Regions
10. GLOBAL GENOME EDITING MARKET ANALYSIS BY GEOGRAPHY
10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
10.3.1 Overview, Historic and Forecast Data Sales Analysis
10.3.2 North America By Segment Sales Analysis
10.3.3 North America By Country Sales Analysis
10.3.4 United States Sales Analysis
10.3.5 Canada Sales Analysis
10.3.6 Mexico Sales Analysis
10.4. Europe Sales Analysis
10.4.1 Overview, Historic and Forecast Data Sales Analysis
10.4.2 Europe By Segment Sales Analysis
10.4.3 Europe By Country Sales Analysis
10.4.4 United Kingdom Sales Analysis
10.4.5 France Sales Analysis
10.4.6 Germany Sales Analysis
10.4.7 Italy Sales Analysis
10.4.8 Russia Sales Analysis
10.4.9 Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
10.5.1 Overview, Historic and Forecast Data Sales Analysis
10.5.2 Asia Pacific By Segment Sales Analysis
10.5.3 Asia Pacific By Country Sales Analysis
10.5.4 China Sales Analysis
10.5.5 India Sales Analysis
10.5.6 Japan Sales Analysis
10.5.7 South Korea Sales Analysis
10.5.8 Australia Sales Analysis
10.5.9 South East Asia Sales Analysis
10.5.10 Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
10.6.1 Overview, Historic and Forecast Data Sales Analysis
10.6.2 Latin America By Segment Sales Analysis
10.6.3 Latin America By Country Sales Analysis
10.6.4 Brazil Sales Analysis
10.6.5 Argentina Sales Analysis
10.6.6 Peru Sales Analysis
10.6.7 Chile Sales Analysis
10.6.8 Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
10.7.1 Overview, Historic and Forecast Data Sales Analysis
10.7.2 Middle East & Africa By Segment Sales Analysis
10.7.3 Middle East & Africa By Country Sales Analysis
10.7.4 Saudi Arabia Sales Analysis
10.7.5 UAE Sales Analysis
10.7.6 Israel Sales Analysis
10.7.7 South Africa Sales Analysis
10.7.8 Rest Of Middle East And Africa Sales Analysis
11. COMPETITIVE LANDSCAPE OF THE GENOME EDITING COMPANIES
11.1. Genome Editing Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments
12. COMPANY PROFILES OF GENOME EDITING INDUSTRY
12.1. Top Companies Market Share Analysis
12.2. Market Concentration Rate
12.3. Merck KGaA
12.3.1 Company Overview
12.3.2 Company Revenue
12.3.3 Products
12.3.4 Recent Developments
12.4. Cibus Inc.
12.4.1 Company Overview
12.4.2 Company Revenue
12.4.3 Products
12.4.4 Recent Developments
12.5. Recombinetics
12.5.1 Company Overview
12.5.2 Company Revenue
12.5.3 Products
12.5.4 Recent Developments
12.6. Sangamo Therapeutics
12.6.1 Company Overview
12.6.2 Company Revenue
12.6.3 Products
12.6.4 Recent Developments
12.7. Editas Medicine
12.7.1 Company Overview
12.7.2 Company Revenue
12.7.3 Products
12.7.4 Recent Developments
12.8. Precision BioSciences
12.8.1 Company Overview
12.8.2 Company Revenue
12.8.3 Products
12.8.4 Recent Developments
12.9. Crispr Therapeutics
12.9.1 Company Overview
12.9.2 Company Revenue
12.9.3 Products
12.9.4 Recent Developments
12.10. Intellia Therapeutics Inc.
12.10.1 Company Overview
12.10.2 Company Revenue
12.10.3 Products
12.10.4 Recent Developments
12.11. Caribou Biosciences Inc
12.11.1 Company Overview
12.11.2 Company Revenue
12.11.3 Products
12.11.4 Recent Developments
12.12. Cellectis S.A.
12.12.1 Company Overview
12.12.2 Company Revenue
12.12.3 Products
12.12.4 Recent Developments
12.13. AstraZeneca
12.13.1 Company Overview
12.13.2 Company Revenue
12.13.3 Products
12.13.4 Recent Developments
12.14. Takara Bio Inc.
12.14.1 Company Overview
12.14.2 Company Revenue
12.14.3 Products
12.14.4 Recent Developments
12.15. Horizon Discovery Ltd. (Revvity Inc.)
12.15.1 Company Overview
12.15.2 Company Revenue
12.15.3 Products
12.15.4 Recent Developments
12.16. Danaher Corporation
12.16.1 Company Overview
12.16.2 Company Revenue
12.16.3 Products
12.16.4 Recent Developments
12.17. Transposagen Biopharmaceuticals Inc.
12.17.1 Company Overview
12.17.2 Company Revenue
12.17.3 Products
12.17.4 Recent Developments
12.18. Genscript Biotech Corp
12.18.1 Company Overview
12.18.2 Company Revenue
12.18.3 Products
12.18.4 Recent Developments
12.19. New England Biolabs
12.19.1 Company Overview
12.19.2 Company Revenue
12.19.3 Products
12.19.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies